Key facts
- ABK Biomedical’s last known valuation is $73.0M (Dec 2022).
- It has raised $121.7M across 4 recorded rounds; the latest was Seed Round ($2.6M) in Oct 2025.
- Notable investors include F-Prime Capital, Eight Roads, Invest Nova Scotia, PIC Investment Group, Atlantic Canada Opportunities Agency — 11 tracked in total.
- ABK Biomedical has filed 4 Form Ds with the SEC since 2019, most recently May 2025 ($26.1M sold to 24 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for ABK Biomedical
Funding rounds
4 roundsAbout ABK Biomedical
Developer of a microsphere product designed to improve the treatment of hypervascular tumors. The company's product is a novel radiopaque bland embolic and beta radiation emitting agent that helps to improve the targeting of tumor vascularity and tumor tissue, enabling doctors to help standardize, optimize, and personalize minimally invasive therapies.
- Sector
- Healthcare
- HQ
- Halifax, Canada
- Founded
- 2012
- Employees
- 41
- Website
- abkbiomedical.com/
- Ownership
- Privately Held (backing)
ABK Biomedical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ABK Biomedical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ABK Biomedical in its N-PORT filings yet. We sweep new filings monthly.